What Makes Ligand Pharmaceuticals (LGND) an Investment Choice?
Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Ligand Pharmaceuticals Inc (LGND)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $105.67 | 5,523 | $583,629.22 | 161,234 | 2025-05-09 | Filing | |
| $104.53 | 2,307 | $241,149.56 | 155,711 | 2025-05-09 | Filing | |
| $104.57 | 1,680 | $175,677.60 | 153,404 | 2025-05-09 | Filing | |
| $104.40 | 500 | $52,200.00 | 27,932 | 2025-05-09 | Filing | |
| $103.89 | 1,000 | $103,890.00 | 27,432 | 2025-05-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $204.26 | 159 | $32,477.77 | 42,253 | 2026-04-01 | Filing | |
| $202.91 | 43 | $8,725.22 | 42,412 | 2026-04-01 | Filing | |
| $202.42 | 79 | $15,991.36 | 42,455 | 2026-04-01 | Filing | |
| $201.24 | 40 | $8,049.40 | 42,534 | 2026-04-01 | Filing | |
| $199.97 | 146 | $29,196.34 | 42,574 | 2026-04-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 504,637 | $100,750,777 | 0.72% | |
| 2. | 19,120 | $3,817,308 | 0.34% | |
| 3. | 16,669 | $3,327,966 | 0.32% | |
| 4. | 3,389 | $676,614 | 0.32% | |
| 5. | 2,698 | $538,494 | 0% |
News See All
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2025 Earnings Call Transcript
Melanie Herman: Good morning, everyone, and welcome to Ligand's Third Quarter 2025 Earnings Call.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Call Transcript August 7, 2025Ligand Pharmaceuticals Incorporated beats earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript May 8, 2025Ligand Pharmaceuticals Incorporated beats earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript February 27, 2025Ligand Pharmaceuticals Incorporated misses on earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Call Transcript
Operator: Good morning. My name is Aaron, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Ligand's Third Quarter 2024 Earnings Call.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Call Transcript August 6, 2024Ligand Pharmaceuticals Incorporated misses on earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.75, expectations were $1.13.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $1.03, expectations were $0.58.
13 Most Promising Small-Cap Stocks According to Analysts
In this piece, we will take a look at the 13 most promising small-cap stocks according to analysts.